Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong ...
Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026 Herantis Pharma has announced positive topline results from its phase 1b trial of HER-096 in people living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback